Literature DB >> 24687924

Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--response.

Robert J G Cardnell1, Lauren A Byers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24687924      PMCID： PMC4098859          DOI： 10.1158/1078-0432.CCR-13-3391

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Therapeutics: PI3K-PARP combination.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

2.  Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.

Authors:  Robert J Cardnell; Ying Feng; Lixia Diao; You-Hong Fan; Fatemah Masrorpour; Jing Wang; Yuqiao Shen; Gordon B Mills; John D Minna; John V Heymach; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

3.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

4.  Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.

Authors:  Deanna M Janzen; Daniel Y Paik; Miguel A Rosales; Brian Yep; Donghui Cheng; Owen N Witte; Huseyin Kayadibi; Christopher M Ryan; Michael E Jung; Kym Faull; Sanaz Memarzadeh
Journal:  Mol Cancer Ther       Date:  2013-11-12       Impact factor: 6.261

5.  Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.

Authors:  Marlena Walls; Sangita M Baxi; Pramod P Mehta; Kevin K-C Liu; Jinjiang Zhu; Heather Estrella; Chunze Li; Michael Zientek; Qing Zong; Tod Smeal; Min-Jean Yin
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531
  5 in total
  2 in total

1.  Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways.

Authors:  Zhongcheng Zhu
Journal:  Oncol Lett       Date:  2018-04-05       Impact factor: 2.967

2.  The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.

Authors:  Liying Ma; Xing Bian; Wenchu Lin
Journal:  J Exp Clin Cancer Res       Date:  2020-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.